{"id":34528,"date":"2025-07-14T08:30:00","date_gmt":"2025-07-14T06:30:00","guid":{"rendered":"https:\/\/ggba.swiss\/comphya-raises-chf-7-5-million-for-its-neurostimulation-therapy-to-treat-erectile-dysfunction\/"},"modified":"2025-07-14T15:42:02","modified_gmt":"2025-07-14T13:42:02","slug":"comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/","title":{"rendered":"Comphya l\u00e8ve CHF 7,5 millions pour sa th\u00e9rapie de neurostimulation contre la dysfonction \u00e9rectile"},"content":{"rendered":"\n<p><a href=\"https:\/\/comphya.com\/\">Comphya SA<\/a>, une start-up medtech bas\u00e9e \u00e0 Lausanne et d\u00e9veloppant une th\u00e9rapie de neurostimulation in\u00e9dite contre la dysfonction \u00e9rectile (DE), a annonc\u00e9 la cl\u00f4ture r\u00e9ussie d\u2019un tour de financement de s\u00e9rie A sursouscrit, portant le total de ses fonds propres lev\u00e9s \u00e0 CHF 7,5 millions (USD 8,4 millions).<\/p>\n\n\n\n<p>La soci\u00e9t\u00e9 d\u00e9veloppe CaverSTIM, le premier neuromodulateur implantable visant \u00e0 restaurer la fonction \u00e9rectile chez les patients ne r\u00e9pondant pas aux traitements conventionnels, notamment les m\u00e9dicaments oraux. Cela inclut les hommes en convalescence apr\u00e8s un cancer de la prostate, un groupe qui manque actuellement d\u2019options th\u00e9rapeutiques efficaces.<\/p>\n\n\n\n<p>D\u00e9but 2025, Comphya avait d\u00e9j\u00e0 lev\u00e9 4,35 millions CHF lors de la premi\u00e8re tranche de sa s\u00e9rie A afin de soutenir un essai clinique de phase I en Australie. Des patients ayant subi une prostatectomie robot-assist\u00e9e ont \u00e9t\u00e9 implant\u00e9s avec le syst\u00e8me CaverSTIM. Les premiers r\u00e9sultats, pr\u00e9sent\u00e9s lors du congr\u00e8s annuel 2025 de l\u2019American Urological Association (AUA) \u00e0 Las Vegas, ont montr\u00e9 des signaux prometteurs en mati\u00e8re de s\u00e9curit\u00e9 et d\u2019efficacit\u00e9 : la majorit\u00e9 des participants ont conserv\u00e9 une fonction \u00e9rectile satisfaisante sans traitement compl\u00e9mentaire, et aucun effet ind\u00e9sirable n\u2019a \u00e9t\u00e9 signal\u00e9.<\/p>\n\n\n\n<p>Les fonds suppl\u00e9mentaires permettront \u00e0 Comphya d\u2019\u00e9largir son essai en Australie et de lancer une \u00e9tude pilote aux \u00c9tats-Unis, <a href=\"https:\/\/comphya.com\/news\/receives-approval-caverstim\/\">apr\u00e8s l\u2019approbation de la FDA dans le cadre d\u2019une autorisation IDE (Investigational Device Exemption)<\/a>. L\u2019\u00e9tude am\u00e9ricaine, d\u00e9j\u00e0 en cours \u00e0 Johns Hopkins, servira \u00e0 concevoir un essai clinique pivot pr\u00e9vu pour 2026. Un nouveau tour de financement (s\u00e9rie B) est envisag\u00e9 pour soutenir cette prochaine phase.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">De l\u2019innovation locale \u00e0 l\u2019ex\u00e9cution clinique mondiale<\/h4>\n\n\n\n<p>Fond\u00e9e comme spin-off de l\u2019EPFL, Comphya s\u2019est impos\u00e9e comme un acteur remarqu\u00e9 de l\u2019\u00e9cosyst\u00e8me medtech de Suisse occidentale, figurant d\u00e9j\u00e0 parmi les innovateurs r\u00e9gionaux menant des essais sur l\u2019humain. Cet investissement marque une nouvelle \u00e9tape dans son passage de l\u2019innovation pr\u00e9coce \u00e0 la validation clinique \u00e0 l\u2019\u00e9chelle internationale.<\/p>\n\n\n\n<p>Ce tour de s\u00e9rie A co\u00efncide \u00e9galement avec un changement de direction : Pim van Wesel, v\u00e9t\u00e9ran de l\u2019industrie, a \u00e9t\u00e9 nomm\u00e9 CEO en mai 2025. \u00ab\u202fNous entamons une nouvelle \u00e9tape cruciale\u202f\u00bb, a-t-il d\u00e9clar\u00e9 dans le communiqu\u00e9 de presse de l\u2019entreprise. \u00ab\u202fAvec le soutien de nos investisseurs, nous sommes bien positionn\u00e9s pour offrir cette th\u00e9rapie innovante aux hommes touch\u00e9s par la dysfonction \u00e9rectile apr\u00e8s un cancer de la prostate.\u202f\u00bb<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La medtech vaudoise Comphya renforce sa feuille de route clinique avec de nouveaux capitaux et pr\u00e9pare des essais pivots aux \u00c9tats-Unis.<\/p>\n","protected":false},"author":6,"featured_media":34525,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1180,1148,1188,1181,1163,1140],"class_list":["post-34528","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-digital-health-fr-2","tag-financing-fr-2","tag-healthcare-fr-2","tag-medical-devices-fr","tag-medtech-fr-2","tag-oncology-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Comphya l\u00e8ve CHF 7,5M pour sa th\u00e9rapie de neurostimulation<\/title>\n<meta name=\"description\" content=\"La medtech vaudoise Comphya renforce sa feuille de route clinique avec de nouveaux capitaux et pr\u00e9pare des essais pivots aux \u00c9tats-Unis.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Comphya l\u00e8ve CHF 7,5M pour sa th\u00e9rapie de neurostimulation\" \/>\n<meta property=\"og:description\" content=\"La medtech vaudoise Comphya renforce sa feuille de route clinique avec de nouveaux capitaux et pr\u00e9pare des essais pivots aux \u00c9tats-Unis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-14T06:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-14T13:42:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Comphya-Device-1180x811-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Comphya l\u00e8ve CHF 7,5 millions pour sa th\u00e9rapie de neurostimulation contre la dysfonction \u00e9rectile\",\"datePublished\":\"2025-07-14T06:30:00+00:00\",\"dateModified\":\"2025-07-14T13:42:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/\"},\"wordCount\":442,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Comphya-Device-1180x811-1.png\",\"keywords\":[\"Digital Health\",\"Financing\",\"Healthcare\",\"Medical Devices\",\"Medtech\",\"Oncology\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/\",\"name\":\"Comphya l\u00e8ve CHF 7,5M pour sa th\u00e9rapie de neurostimulation\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Comphya-Device-1180x811-1.png\",\"datePublished\":\"2025-07-14T06:30:00+00:00\",\"dateModified\":\"2025-07-14T13:42:02+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"La medtech vaudoise Comphya renforce sa feuille de route clinique avec de nouveaux capitaux et pr\u00e9pare des essais pivots aux \u00c9tats-Unis.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Comphya-Device-1180x811-1.png\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Comphya-Device-1180x811-1.png\",\"width\":1180,\"height\":811,\"caption\":\"CaverSTIM de Comphya est le premier neurostimulateur implantable con\u00e7u pour restaurer la fonction \u00e9rectile apr\u00e8s une chirurgie de la prostate. | \u00a9 Comphya\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Comphya l\u00e8ve CHF 7,5 millions pour sa th\u00e9rapie de neurostimulation contre la dysfonction \u00e9rectile\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Comphya l\u00e8ve CHF 7,5M pour sa th\u00e9rapie de neurostimulation","description":"La medtech vaudoise Comphya renforce sa feuille de route clinique avec de nouveaux capitaux et pr\u00e9pare des essais pivots aux \u00c9tats-Unis.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/","og_locale":"fr_FR","og_type":"article","og_title":"Comphya l\u00e8ve CHF 7,5M pour sa th\u00e9rapie de neurostimulation","og_description":"La medtech vaudoise Comphya renforce sa feuille de route clinique avec de nouveaux capitaux et pr\u00e9pare des essais pivots aux \u00c9tats-Unis.","og_url":"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-07-14T06:30:00+00:00","article_modified_time":"2025-07-14T13:42:02+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Comphya-Device-1180x811-1.png","type":"image\/png"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Comphya l\u00e8ve CHF 7,5 millions pour sa th\u00e9rapie de neurostimulation contre la dysfonction \u00e9rectile","datePublished":"2025-07-14T06:30:00+00:00","dateModified":"2025-07-14T13:42:02+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/"},"wordCount":442,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Comphya-Device-1180x811-1.png","keywords":["Digital Health","Financing","Healthcare","Medical Devices","Medtech","Oncology"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/","url":"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/","name":"Comphya l\u00e8ve CHF 7,5M pour sa th\u00e9rapie de neurostimulation","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Comphya-Device-1180x811-1.png","datePublished":"2025-07-14T06:30:00+00:00","dateModified":"2025-07-14T13:42:02+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"La medtech vaudoise Comphya renforce sa feuille de route clinique avec de nouveaux capitaux et pr\u00e9pare des essais pivots aux \u00c9tats-Unis.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Comphya-Device-1180x811-1.png","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/07\/Comphya-Device-1180x811-1.png","width":1180,"height":811,"caption":"CaverSTIM de Comphya est le premier neurostimulateur implantable con\u00e7u pour restaurer la fonction \u00e9rectile apr\u00e8s une chirurgie de la prostate. | \u00a9 Comphya"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/comphya-leve-chf-75-millions-pour-sa-therapie-de-neurostimulation-contre-la-dysfonction-erectile\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Comphya l\u00e8ve CHF 7,5 millions pour sa th\u00e9rapie de neurostimulation contre la dysfonction \u00e9rectile"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/34528","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=34528"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/34528\/revisions"}],"predecessor-version":[{"id":34530,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/34528\/revisions\/34530"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/34525"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=34528"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=34528"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=34528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}